Polycystic Kidney Disease Drugs Market - Regional Analysis
North American Market Forecast
North America industry is predicted to dominate majority revenue share by 2035. The growth of the market can be attributed majorly to the rise in per capita income, along with rising awareness of the early diagnosis of chronic kidney diseases as of the advancement in the medical array in the region. In accordance with data provided by the World Bank, the annual income of each individual in the United States rose by USD 69287.5 in 2021 from USD 63027.7 in the year 2020. Further, the presence of affordable healthcare policies in the region, along with intensive drug research and development, is also anticipated to contribute to the market growth in the region. In addition, a significant increase in the medical and healthcare industries, easy drug accessibility, and dynamic surge in dialysis procedures are further expected to fuel the global polycystic kidney disease drugs market in the region during the forecast period.
APAC Market Statistics
Furthermore, the Asia Pacific polycystic kidney disease drugs market is anticipated to display notable market growth by the end of 2035. The growth of the market can be attributed to the mounting proportion of chronic kidney disorders, coupled with the developing healthcare facilities in emerging nations such as China, India, and so on. For instance, in 2019, there were around 9 million new cases and nearly 783 035 fatalities owing to CKD in the Asia Pacific region. Between 1990 and 2019, the region's CKD prevalence more than doubled, rising from around 203.8 million to 433.6 million. In addition to this, the increasing initiatives by the government of nations to raise awareness about chronic kidney disorders, along with the escalating ratio of aging people, are some further factors that are anticipated to propel the market growth throughout the projected time frame in the region.
